Compare L3Harris Technologies Inc (LHX) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Smith & Nephew plc — how do they compare? L3Harris Technologies Inc trades at $236.97 (market cap $44.12B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: L3Harris Technologies Inc is far larger — about 4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold L3Harris Technologies Inc for 56 Days and Smith & Nephew plc for 121 Days on average.
| LHX | SNN | |
|---|---|---|
Market Cap | $44.12B | $11.10B |
Volume | 1,202,852 | 1,051,703 |
Sector | Industrials | Health |
52-Week High | $378.48 | $37.17 |
52-Week Low | $233.63 | $26.42 |
Typical Hold Time | 56 Days | 121 Days |
Enterprise Value | $54.56B | $14.13B |
Dividend Yield | 2.11% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $236.92, up 1.41% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 7.34% net income margin. The company secured major defense contracts totaling over $10.7 billion recently, while technical indicators show bearish momentum despite positive analyst sentiment with a $340 consensus price target representing 44% upside potential.
LHX presents a compelling investment case with robust defense contract wins and improving profitability, though investors face headwinds from multiple law firm investigations and bearish technical signals. The stock's current valuation appears reasonable with a P/E of 23.93, but legal uncertainties require careful monitoring alongside the company's strong defense sector positioning.
SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.
The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
